Efficacy and safety of premixed versus basal‐bolus regimens as intensification of insulin therapy in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis of randomized clinical trials

Documenti analoghi

• Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study
  di: Leili Gao, et al.
  Pubblicazione: (2025)
• A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02)
  di: Yushi Hirota, et al.
  Pubblicazione: (2024)
• An update of contemporary insulin therapy
  di: Yuan‐Yu Tsai, et al.
  Pubblicazione: (2024)
• Development of a diagnostic model of insulin‐related lipohypertrophy for patients with diabetes mellitus
  di: Xiaohui Li, et al.
  Pubblicazione: (2025)
• Diabetes remission in newly diagnosed type 2 diabetes mellitus through short‐term continuous subcutaneous insulin infusion intensive therapy combined with low‐carbohydrate diet treatment
  di: Xuemei Huang, et al.
  Pubblicazione: (2024)